Anja Schiemann

Dr. Anja Schiemann

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
HRHenry Rosenberg
Henry Rosenberg
NPNeil Pollock
Neil Pollock
ASAnja Schiemann
Anja Schiemann
TBTerasa Bulger
Terasa Bulger
KSKathryn Stowell
Kathryn Stowell
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine, and rarely, in humans, to stressors such as vigorous exercise and heat. The incidence of MH reactions ranges from 1:10,000 to 1: 250,000 anesthetics. However, the prevalence of the genetic abnormalities may be as great as one in 400 individuals. MH affects humans, certain pig breeds, dogs and horses. The classic signs of MH include hyperthermia, tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, hyperkalaemia, muscle rigidity, and rhabdomyolysis, all related to a hypermetabolic response. The syndrome is likely to be fatal if untreated. An increase in end-tidal carbon dioxide despite increased minute ventilation provides an early diagnostic clue. In humans the syndrome is inherited in an autosomal dominant pattern, while in pigs it is autosomal recessive. Uncontrolled rise of myoplasmic calcium, which activates biochemical processes related to muscle activation leads to the pathophysiologic changes. In most cases, the syndrome is caused by a defect in the ryanodine receptor. Over 400 variants have been identified in the RYR1 gene located on chromosome 19q13.1, and at least 34 are causal for MH. Less than 1 % of variants have been found in CACNA1S but not all of these are causal. Diagnostic testing involves the in vitro contracture response of biopsied muscle to halothane, caffeine, and in some centres ryanodine and 4-chloro-m-cresol. Elucidation of the genetic changes has led to the introduction of DNA testing for susceptibility to MH. Dantrolene sodium is a specific antagonist and should be available wherever general anesthesia is administered. Increased understanding of the clinical manifestation and pathophysiology of the syndrome, has lead to the mortality decreasing from 80 % thirty years ago to <5 % in 2006.

10 January 2012 in Insect Molecular Biology
Verified
Journal Article
Closed access
PDF file
CCC. Concha
C. Concha
RER. M. Edman
R. M. Edman
EBE. J. Belikoff
E. J. Belikoff
ASAnja Schiemann
Anja Schiemann
BCB. Carey
B. Carey
MSMaxwell Scott
Maxwell Scott

1 February 2008 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
FLFang Li
Fang Li
ASAnja Schiemann
Anja Schiemann
MSMaxwell J. Scott
Maxwell J. Scott
The male-specific lethal (MSL) protein-RNA complex is required for X chromosome dosage compensation in Drosophila melanogaster. The MSL2 and MSL1 proteins form a complex and are essential for X chromosome binding. In addition, the MSL complex must integrate at least one of the noncoding roX RNAs for normal X chromosome binding. Here we find the amino-terminal RING finger domain of MSL2 binds as a complex with MSL1 to the heterochromatic chromocenter and a few sites on the chromosome arms. This binding required the same amino-terminal basic motif of MSL1 previously shown to be essential for binding to high-affinity sites on the X chromosome. While the RING finger domain of MSL2 is sufficient to increase the expression of roX1 in females, activation of roX2 requires motifs in the carboxyl-terminal domain. Binding to hundreds of sites on the X chromosome and efficient incorporation of the roX RNAs into the MSL complex require proline-rich and basic motifs in the carboxyl-terminal domain of MSL2. We suggest that incorporation of the roX RNAs into the MSL complex alters the binding specificity of the chromatin-binding module formed by the amino-terminal domains of MSL1 and MSL2.

1 January 2011 in Insect Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
CCCarolina Concha
Carolina Concha
EBEsther J. Belikoff
Esther J. Belikoff
BCBrandi-Lee Carey
Brandi-Lee Carey
FLFang Li
Fang Li
ASAnja Schiemann
Anja Schiemann
MSMaxwell Scott
Maxwell Scott

4 May 2016 in British Journal of Anaesthesia
Verified
Journal Article
Open access
PDF file
ASAnja Schiemann
Anja Schiemann
KSK. M. Stowell
K. M. Stowell
Malignant hyperthermia (MH) is a pharmacogenetic disorder that has been linked to the skeletal muscle calcium release channel (RYR1) and the α1S subunit of the voltage-dependent L-type calcium channel (CACNA1S). Genomic DNA capture and next generation sequencing are becoming the preferred method to identify mutations in these genes. Bioinformatic pathogenicity prediction of identified variants may help to determine if these variants are in fact disease causing. Eight pathogenicity prediction programmes freely available on the web were used to determine their ability to correctly predict the impact of a missense variant on RyR1 or dihydropyridine receptor (DHPR) protein function. We tested MH-causative variants, variants that had been shown to alter calcium release in cells, and common sequence variants in RYR1 and CACNA1S. None of the prediction programmes was able to identify all of the variants tested correctly as either ‘damaging’ (MH-causative variants, variants that had been shown to alter calcium release in cells) or as ‘benign’ (common sequence variants). The overall sensitivity of predictions ranged from 84% to 100% depending on the programme used, with specificity from 25% to 83%. In this study we determined the sensitivity and specificity of bioinformatic pathogenicity prediction tools for RYR1 and CACNA1S. We suggest that the prediction results should be treated with caution, as none of the programmes tested predicted all the variants correctly and should only be used in combination with other available data (functional assays, segregation analysis).

1 September 2014 in Cell Calcium
Verified
Journal Article
Closed access
CRCornelia Roesl
Cornelia Roesl
KSKeisaku Sato
Keisaku Sato
ASAnja Schiemann
Anja Schiemann
NPNeil Pollock
Neil Pollock
KSKathryn Stowell
Kathryn Stowell